Sai Reddemma Indukuri

Antibody-drug conjugates as promising platform for intrahepatic cholangiocarcinoma: molecular insights, drug-delivery challenges, and emerging therapeutic targets.

Intrahepatic cholangiocarcinoma (iCCA) is the second most prevalent primary hepatic malignancy with increasing incidence, poor prognosis, recurrence, and limited therapies. Currently, surgical resection remains the only potentially curative treatment for iCCA. The main challenge, even after surgery, is that small or po...